Cargando…
The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
BACKGROUND: Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols. PATIENTS AND METHODS: Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809144/ https://www.ncbi.nlm.nih.gov/pubmed/35198464 http://dx.doi.org/10.4103/idoj.idoj_530_21 |
_version_ | 1784643958780985344 |
---|---|
author | Manvi, Sujaya Mahajan, Vikram K. Mehta, Karaninder S. Chauhan, Pushpinder S. Vashist, Sanket Singh, Ravinder Kumar, Prabal |
author_facet | Manvi, Sujaya Mahajan, Vikram K. Mehta, Karaninder S. Chauhan, Pushpinder S. Vashist, Sanket Singh, Ravinder Kumar, Prabal |
author_sort | Manvi, Sujaya |
collection | PubMed |
description | BACKGROUND: Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols. PATIENTS AND METHODS: Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019 were analyzed retrospectively for clinical attributes, putative drugs and their indications, extracutaneous complications, and therapeutic outcome. The diagnosis was clinical based on established criteria. WHO-UMC scale for reporting ADR and ALDEN algorithm score were used for causality assessment. Therapies were customized based on in-house resources and affordability. RESULTS: Cases included were SJS (41.9%), SJS/TEN overlap (33.9%), and TEN (24.2%) aged 4–85 years. Complications included transaminitis (69.4%), lymphadenopathy (15.5%), septicemia (11.3%), and wound infections (4.8%). Aromatic anticonvulsants (37.1%), disease-modifying antirheumatic drugs (25.8%), antiretroviral drugs (12.9%), non-steroidal anti-inflammatory drugs (8.1%), antimicrobials (4.8%), and trihexyphenidyl (3.2%) were major putative drugs. The mean latent period was 16.6 days. The observed 8% mortality was because of primary comorbidities or multiorgan failure. Addition of fresh blood transfusion (BT, n = 11) or IVIg (n = 7) to systemic corticosteroids showed early relief in skin tenderness, improvement in general condition, and re-epithelialization. Only 16% of patients developed sequelae. CONCLUSION: Aromatic anticonvulsants, allopurinol, nevirapine, cotrimoxazole, paracetamol, and diclofenac remain the most implicated drugs. Sulfasalazine, leflunomide, ethambutol, and trihexyphenidyl were uncommon additions. A short course of high-dose dexamethasone in the early stage was useful. Addition of BT or IVIg provided rapid relief. Preexisting HIV disease, kidney disease, and sepsis remain important for in-hospital deaths. Retrospective study design and small number of cases remain major limitations. |
format | Online Article Text |
id | pubmed-8809144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-88091442022-02-22 The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study Manvi, Sujaya Mahajan, Vikram K. Mehta, Karaninder S. Chauhan, Pushpinder S. Vashist, Sanket Singh, Ravinder Kumar, Prabal Indian Dermatol Online J Original Article BACKGROUND: Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols. PATIENTS AND METHODS: Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019 were analyzed retrospectively for clinical attributes, putative drugs and their indications, extracutaneous complications, and therapeutic outcome. The diagnosis was clinical based on established criteria. WHO-UMC scale for reporting ADR and ALDEN algorithm score were used for causality assessment. Therapies were customized based on in-house resources and affordability. RESULTS: Cases included were SJS (41.9%), SJS/TEN overlap (33.9%), and TEN (24.2%) aged 4–85 years. Complications included transaminitis (69.4%), lymphadenopathy (15.5%), septicemia (11.3%), and wound infections (4.8%). Aromatic anticonvulsants (37.1%), disease-modifying antirheumatic drugs (25.8%), antiretroviral drugs (12.9%), non-steroidal anti-inflammatory drugs (8.1%), antimicrobials (4.8%), and trihexyphenidyl (3.2%) were major putative drugs. The mean latent period was 16.6 days. The observed 8% mortality was because of primary comorbidities or multiorgan failure. Addition of fresh blood transfusion (BT, n = 11) or IVIg (n = 7) to systemic corticosteroids showed early relief in skin tenderness, improvement in general condition, and re-epithelialization. Only 16% of patients developed sequelae. CONCLUSION: Aromatic anticonvulsants, allopurinol, nevirapine, cotrimoxazole, paracetamol, and diclofenac remain the most implicated drugs. Sulfasalazine, leflunomide, ethambutol, and trihexyphenidyl were uncommon additions. A short course of high-dose dexamethasone in the early stage was useful. Addition of BT or IVIg provided rapid relief. Preexisting HIV disease, kidney disease, and sepsis remain important for in-hospital deaths. Retrospective study design and small number of cases remain major limitations. Wolters Kluwer - Medknow 2022-01-24 /pmc/articles/PMC8809144/ /pubmed/35198464 http://dx.doi.org/10.4103/idoj.idoj_530_21 Text en Copyright: © 2022 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Manvi, Sujaya Mahajan, Vikram K. Mehta, Karaninder S. Chauhan, Pushpinder S. Vashist, Sanket Singh, Ravinder Kumar, Prabal The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study |
title | The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study |
title_full | The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study |
title_fullStr | The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study |
title_full_unstemmed | The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study |
title_short | The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study |
title_sort | clinical characteristics, putative drugs, and optimal management of 62 patients with stevens-johnson syndrome and/or toxic epidermal necrolysis: a retrospective observational study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809144/ https://www.ncbi.nlm.nih.gov/pubmed/35198464 http://dx.doi.org/10.4103/idoj.idoj_530_21 |
work_keys_str_mv | AT manvisujaya theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT mahajanvikramk theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT mehtakaraninders theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT chauhanpushpinders theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT vashistsanket theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT singhravinder theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT kumarprabal theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT manvisujaya clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT mahajanvikramk clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT mehtakaraninders clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT chauhanpushpinders clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT vashistsanket clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT singhravinder clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy AT kumarprabal clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy |